McAllister, Thomas W.Zafonte, RossJain, SoniaFlashman, Laura A.George, Mark S.Grant, Gerald A.He, FengLohr, James B.Andaluz, NorbertoSummerall, LanierPaulus, Martin P.Raman, RemaStein, Murray B.2017-10-172017-10-172016-04McAllister, T. W., Zafonte, R., Jain, S., Flashman, L. A., George, M. S., Grant, G. A., … Stein, M. B. (2016). Randomized Placebo-Controlled Trial of Methylphenidate or Galantamine for Persistent Emotional and Cognitive Symptoms Associated with PTSD and/or Traumatic Brain Injury. Neuropsychopharmacology, 41(5), 1191–1198. http://doi.org/10.1038/npp.2015.2821740-634Xhttps://hdl.handle.net/1805/14312We report findings from a 12-week randomized double-blinded placebo-controlled trial of methylphenidate or galantamine to treat emotional and cognitive complaints in individuals (n=32) with a history of PTSD, TBI, or both conditions. In this small pilot study, methylphenidate treatment was associated with clinically meaningful and statistically significant improvement compared with placebo on the primary outcome, a measure of cognitive complaints (Ruff Neurobehavioral Inventory-Postmorbid Cognitive Scale), as well as on the secondary outcomes reflecting post-concussive (Rivermead Post Concussive Symptom Questionnaire) and post-traumatic stress symptoms (Posttraumatic Stress Disorder Checklist). Treatment was well tolerated. These results suggest the need for a larger RCT to replicate and confirm these findings. Design considerations for such a trial should include the need for multiple sites to facilitate adequate recruitment and extension of the treatment and follow-up periods.en-USPublisher PolicyBrain Injuries, Traumaticdrug therapypsychologyGalantaminetherapeutic useMethylphenidateStress Disorders, Post-TraumaticArticle